![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
When you’re lost, navigation apps like Waze help you to find your way. They “know” what’s happening up ahead beyond your view, and put you on the right road. Waze adds a special twist beyond conventional GPS, gathering...
Five things for pharma marketers to know: Wednesday, November 27, 2019
Federal prosecutors have begun a criminal investigation of opioid makers. Companies including Teva, McKesson, Mallinckrodt, AmerisourceBergen, Johnson & Johnson and Amneal Pharmaceuticals have received subpoenas...
Contentmarketing: maak het persoonlijk
Contentmarketing Emotie en beleving. Daar draaide het allemaal om op het Congres Contentmarketing en Webredactie 2019. In de Jaarbeurs waren de keynotes en talks gericht op het gevoel dat gebruikers krijgen bij een...
Pharmazz begins patient dosing in phase 3 study of sovateltide to treat acute cerebral ischemic stroke
Sovateltide Pharmazz, Inc, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced the initiation of dosing in its pivotal, phase...
Drones helpen bij medisch transport
Medisch transport Zorg- en mobiliteitspartners vormen samenwerkingsverband: Medical Drone Service Bij het Erasmus MC werd onlangs het startsein gegeven voor een pilot met medische drones. Het Erasmus MC en Sanquin...
Vijf redenen waarom je alle marketingtrends voor 2020 het best kunt negeren
Marketingtrends voor 2020 Virtuele influencers. Voice search. Hypertargeting. Chatbots. TikTok. Je zou wel gek zijn als je deze marketingtrends voor 2020 over het hoofd zou zien. Althans, als je het vooral belangrijk...
Novartis acquires The Medicines Company in a deal worth $9.7 billion
Novartis agreed a $9.7 billion deal to acquire the US-based The Medicines Company, it announced Sunday. The transaction was unanimously approved by the boards of both companies and Novartis will pay $85 per share. This...
Marketeers zijn kansloos zonder experimentele cultuur
Een discussie die in mijn beleving nooit is weggeweest lijkt weer op te laaien. Werkt reclame eigenlijk wel? Worden de investeringen in reclame en media wel terugverdiend? Artikelen uit De Correspondent worden...
Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo
MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of metastatic or unresectable recurrent head and neck squamous...
Bristol-Myers misses main goal of late-stage skin cancer trial
late-stage skin cancer trial Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of...
Allergan’s acute migraine therapy ubrogepant shows strength at Phase 3
Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s strength compared to placebo in the acute treatment of migraine...
Wijziging hulpmiddelenzorg in Wlz-instellingen
Wet langdurige zorg (Wlz) Vanaf 1 januari 2020 worden rolstoelen en scootmobielen voor mensen in een Wlz-instelling verstrekt uit één regeling: de Wet langdurige zorg (Wlz). De veranderingen gelden alleen voor mensen...
EMA committee recommends approval for Jazz Pharma’s solriamfetol to improve wakefulness & reduce EDS in adults with narcolepsy/obstructive sleep apnea
Reduction in EDS: Jazz Pharmaceuticals, a global biopharmaceutical company, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion...
Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery
Artificial Intelligence algorithm: Artificial Intelligence algorithm can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of...
EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis
Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of secondary progressive multiple...
Merck and Bayer’s heart drug meets main goal of late-stage study
Merck and Bayer said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.
AstraZeneca presents results from positive phase III TULIP 2 trial for anifrolumab to treat SLE at ACR meeting
AstraZeneca presents detailed results from the positive phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of moderate to severe systemic lupus erythematosus (SLE), which demonstrated...
Clinical trial: Oral drug improves exercise capacity in teens with congenital heart defects
The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity in adolescent patients with severe, congenital single-ventricle heart...
